Two targeted therapies, dabrafenib (Taflinar®) plus trametinib (Mekinst®), significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in pediatric patients with BRAF V600 mutation-positive low-grade gliomas. Secondary findings showed an improved clinical benefit rate and prolonged progression-free survival for dabrafenib plus trametinib compared to carboplatin plus vincristine, according to new research that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 6, 2022
June 5, 2022
The use of panitumumab (Vectibix®) plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer that was classified as left-sided compared to patients who received mFOLFOX6, a standard chemotherapy regimen, plus bevacizumab (Avastin®), a monoclonal antibody, according to a finding that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 5, 2022
The use of autologous stem cell transplant (ASCT) early in the course of treatment showed a significant 21.4-month gain in median progression-free survival in younger, newly diagnosed multiple myeloma patients compared to patients who received chemotherapy without an initial transplant. No overall survival benefit has yet been seen using ASCT early compared to keeping it in reserve.
June 5, 2022
The use of trastuzumab deruxtecan (Enhertu®), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival compared to standard-of-care treatment with conventional chemotherapy. It also significantly improved overall survival for patients with metastatic breast cancers expressing low levels of the HER2 receptor, regardless of hormone receptor status. These practice-changing findings identify a new subset of breast cancer - called HER2-low - and redefine how a large proportion of metastatic patients will be treated. This new research will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 5, 2022
Use of high-dose ifosfamide (Ifex®) was found to be superior for treating recurrent and primary refractory Ewing sarcoma compared to three other standard-of-care treatments that are used for the disease, according to research that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 4, 2022
The use of sacituzumab govitecan (Trodelvy®) an antibody-drug conjugate, resulted in longer progression-free survival compared to physician’s choice of chemotherapy in patients who have received many prior therapies and who had hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, according to new research to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 3, 2022
Ibrutinib (Imbruvica™) combined with bendamustine-rituximab improved progression-free survival by 50% for older patients with newly diagnosed mantle cell lymphoma compared to patients who received a placebo plus bendamustine-rituximab, according to new research that will be reported at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 3, 2022
The addition of nimotuzumab to gemcitabine (Gemzar®) increases overall survival in patients with K-Ras wild-type advanced pancreatic cancer, particularly for patients who did not need surgery for obstruction of a pancreatic bile duct, according to new research to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 26, 2022
With the rapid acceleration of the spread of the COVID-19 virus in the United States in March 2020, telemedicine visits became more common for cancer care. However, in an evaluation of telemedicine inequities in 21 common cancers, there were distinctly lower levels of telemedicine use by Black patients and those who were uninsured, lived in suburban or rural areas, and resided in a neighborhood with low socioeconomic status. The research will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 26, 2022
A survey of metastatic breast cancer patients found that 83% of Black respondents were somewhat or very likely to consider clinical trial participation; however, 40% of those respondents reported that they had not been informed by their care team about the opportunity to enroll in a trial. The research will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 26, 2022
States that increased investments in social services spending by 10% compared to those that did not increase spending – including Medicaid and other social services for socioeconomically disadvantaged individuals – showed improved five-year overall survival for non-Hispanic Black adults with cancer, according to new research. There was also a decrease in racial disparities in survival between non-Hispanic Black and white patients for many different types of cancers. The study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 26, 2022
Children with high-risk neuroblastoma from historically marginalized racial and ethnic groups had a higher probability of dying than other children despite equal planned treatment on pediatric clinical trials, according to research that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 3, 2022
Oncology professionals from around the world will convene in Chicago to discuss the latest clinical cancer research impacting patient care at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Advances in therapies for rare and pediatric cancers, findings on disparities among patients with cancer, and new treatment options for patients with advanced breast, colorectal, and pancreatic cancers are among the topics that will be highlighted in the meeting’s official Press Program.
March 14, 2022
Patients with advanced non-small cell lung cancer without EGFR/ALK mutations who were treated with toripalimab plus first-line chemotherapy had better progression-free survival and overall survival compared to patients who received chemotherapy alone, according to research from the CHOICE-01 trial.
March 14, 2022
In patients with previously untreated metastatic or unresectable melanoma, the combination of nivolumab and relatlimab continued to demonstrate a progression-free survival benefit compared to nivolumab alone. The combination also demonstrated for the first time a higher overall response rate according to follow-up data from the RELATIVITY-047 trial. These data will be presented during an ASCO Plenary Series session taking place March 15, 2022, at 5:00 p.m. ET.
Pages |